Apaxen is a privately-held biotechnology company developing innovative treatments for patients with diseases that depend on chronic NLRP3 Inflammasome activation.

We develop first-in-class small molecule inhibitors of NLRP3 Inflammasome activation, a key driver of inflammation in many diseases. Our drugs work by blocking the intracellular interaction of Macrophage Migration Inhibitory Factor (MIF) and NLRP3, a novel approach which has shown to be highly effective to inhibit the construction and activation of NLRP3 Inflammasomes. 

Apaxen’s lead compound, MFC-1040 has the potential te become an effective treatment for many inflammatory and auto-immune diseases. With the growing understanding of the importance of NLRP3 inflammasomes for the progression of inflammatory diseases, the list of diseases that could be successfully treated with MFC-1040 is rapidly becoming longer.

Our platform for the discovery and development intends to generate a pipeline of differentiated MIF/NLRP3 Inflammasome inhibitors for treatment of inflammatory and autoimmune diseases, ranging from neuro-inflammation to peripheral inflammatory diseases.